Overview |
bsm-54712R |
HMGN2 Monoclonal Antibody |
WB, IHC-P, IF(ICC) |
Human |
Specifications |
Unconjugated |
Rabbit |
Synthetic Peptide within N terminal human HMGN2. |
Monoclonal |
8H5 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at -20°C for 12 months. |
Target |
3151 |
P05204 |
Cytoplasm, Nucleus |
High mobility group (nonhistone chromosomal) protein 17 antibody, high mobility group nucleosomal binding domain 2 antibody, High mobility group nucleosome-binding domain-containing protein 2 antibody, High mobility group protein N2 antibody, HMG17 antibody, HMGN2 antibody, HMGN2_HUMAN antibody, MGC5629 antibody, Non histone chromosomal protein HMG 17 antibody, Non-histone chromosomal protein HMG-17 antibody, Nonhistone chromosomal protein HMG 17 antibody, nonhistone chromosomal protein hmg-17 antibody |
The high-mobility group (HMG) proteins 14 and 17 are abundant chromosomal proteins that bind to nucleosomes and enhance transcription (15). HMG-14 and HMG-17 also function as architectural elements, which alter the structure of the chromatin fiber and enhance transcription from chromatin templates (13,5). HMG-14/17 proteins modify the nucleosomal organization of the 30 nm chromatin fiber and mediate the unfolding of the higher order chromatin structure thereby facilitating access to the underlying DNA sequence (13). Clustering of architectural elements, such as HMG proteins and linker histone subtypes into distinct domains, may lead to structural and functional heterogeneity along the chromatin fiber (13). In addition, HMG-14 and HMG-17 have been identified as constitutive components of mouse oocyte and embryonic chromatin that establish a link between the structure of embryonic chromatin and the normal progression of embryonic development (2). |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(ICC) |
1:50-200 |